Literature DB >> 9039718

Fixed dose combinations of ACE inhibitors.

B Rangoonwala1, W Schulz, B Bauer.   

Abstract

First-line antihypertensive monotherapy is effective in reducing blood pressure to within the normal range in approximately 50% of patients. Normalisation in the remaining patients may require a combination of two or more drugs. This review considers the clinical efficacy and tolerability of combinations involving angiotensin-converting enzyme (ACE) inhibitors. The efficacy of combinations with diuretics or calcium antagonists, as initial therapy or in patients with inadequate responses to monotherapy, has been demonstrated in many trials. With combination therapy, normalisation rates approaching 80% can be achieved using submaximal doses of both components. Therapy with both combinations is well tolerated; with ACE inhibitors reducing the diuretic metabolic effects or counteracting some calcium antagonist-associated vasodilatory effects. Data on ACE inhibitors with beta-blockers are limited. When patients respond inadequately to first-line monotherapy, the increasing availability of drug combinations will allow individual selection of the most appropriate combination, taking account of additional risk factors and concomitant disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9039718

Source DB:  PubMed          Journal:  Br J Clin Pract        ISSN: 0007-0947


  3 in total

1.  Impact of Modified System of Objectified Judgement Analysis (SOJA) methodology on prescribing costs of ACE inhibitors.

Authors:  Ibrahim Alabbadi; Grainne Crealey; Michael Scott; Simon Baird; Tom Trouton; Jill Mairs; James McElnay
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

Review 2.  Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats.

Authors:  Domenic A Sica
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 3.  Reducing cardiovascular events in high-risk patients: the challenge of managing hypertension in patients with diabetic renal disease.

Authors:  Robert D Toto
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-11       Impact factor: 3.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.